<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01731080</url>
  </required_header>
  <id_info>
    <org_study_id>AOI-2011</org_study_id>
    <nct_id>NCT01731080</nct_id>
  </id_info>
  <brief_title>Arterial Wall Calcium Load in Pseudoxanthoma Elasticum</brief_title>
  <acronym>Ca-Art-PXE2</acronym>
  <official_title>Arterial Wall Calcium Load and Preferential Sites in Pseudoxanthoma Elasticum Versus Type 2 Diabetes and Chronic Kidney Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Quantification and preferential sites of arterial wall calcification within the coronary and
      lower legs arteries will be comared between Pseudo-Xanthoma elasticum(PXE) atients and type 2
      diabetics and Chronic Kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a previous work we have observed that patients suffering from PXE, a soft-tissue
      calcifying inherited autosomal disease, exhibited specific structural and functionnal
      features within the peripheral arteries. We now want to quantify and determine the
      preferential sites of the arterial wall calcification (Agatston score) between these patients
      compared to diabetics and patients with chronic renal insufficiency with mediacalcosis.

      All variables will be collected from a cohort of PXE monitored in our PXE Health and Care
      centre at the university hospital of Angers. Quantification of the arterial wall calcium load
      will be performed using helicoidal CT-scan. These variables will be compared to the same
      measurements performed in type 2 diabetic and chronic kidney disease patients paired by age
      and gender.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>calcification score</measure>
    <time_frame>after inclusion</time_frame>
    <description>the level of arterial wall calcification determined by a Ct-scan and computed by the Agatston score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>site of calcification</measure>
    <time_frame>after inclusion</time_frame>
    <description>the anatomical site of arterial wall calcification determined by a Ct-scan and computed by the Agatston score</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pseudoxanthoma Elasticum</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Pseudoxanthoma Elasticum</arm_group_label>
    <description>Patients with genetically and clincally proven PXE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic kidney disease</arm_group_label>
    <description>Type 2 diabetic patients with mediacalcosis and matched to PXE patients for gender and age (+/- 5 yrs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes</arm_group_label>
    <description>patients with chronic kidney disease and matched to PXE patients for gender and age (+/- 5 yrs).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pseudoxanthoma Elasticum (PXE)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with phenotypically and genotypically-proven PXE

          -  Type 2 diabetic patients with mediacalcosis (i.e. Ankle Brachial Index &gt; 1.30)

          -  Patients with a chronic kidney disease (CKD), before kidney transplantation

          -  All patients should be affiliated to a Health care system

        Exclusion Criteria:

          -  Patient with unproved PXE

          -  Patient under the age of 18 yrs

          -  Patient unwilling to participate to the study

          -  Pregnant women

          -  Patient not affiliated to a Health care system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yannick LE CORRE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, University Hospital of Angers, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yannick LE CORRE, MD</last_name>
    <phone>33(2)41.35.39.10</phone>
    <email>yalecorre@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ludovic MARTIN, MD, PhD</last_name>
    <phone>33(2)41.35.34.19</phone>
    <email>lumartin@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Angers</city>
        <state>Pays de la Loire</state>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludovic MARTIN, MD, PhD</last_name>
      <phone>33(2)41.35.34.19</phone>
      <email>lumartin@chu-angers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Georges LEFTHERIOTIS, MD, PhD</last_name>
      <phone>33(2)41.35.44.56</phone>
      <email>geleftheriotis@chu-angers.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Yannick LE CORRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ludovic MARTIN, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georges LEFTHERIOTIS, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre ABRAHAM, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge WILLOTEAUX, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Francois SUBRA, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Henri DUCLUZEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2012</study_first_submitted>
  <study_first_submitted_qc>November 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2012</study_first_posted>
  <last_update_submitted>November 20, 2012</last_update_submitted>
  <last_update_submitted_qc>November 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Pseudoxanthoma Elasticum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

